What is the test asking?

Accepted specimen

Intact whole blood

Named additive/container

Lavender-top EDTA tube

A CBC examines blood cells. Removing plasma for another test does not leave an acceptable substitute for this intact EDTA whole-blood order.

The rejection list includes clots, other anticoagulants, transferred whole blood, and specimens with plasma removed. This is not a separated-plasma submission.

The current 005009 title includes reflex smear review; it is not simply every CBC variant. No pediatric volume or inversion instruction is carried into this example.

Accepted specimen

Whole blood

Named additive/container

EDTA, lithium heparin or sodium fluoride tubes listed by this assay

Both HbA1c and CBC can use whole blood, yet their accepted additives are not identical. Here HbA1c is not EDTA-only; the named assay controls acceptance.

The whole specimen is submitted without clots. Its accepted anticoagulants differ from the CBC example.

Shortened red-cell survival, hemoglobin variants and assay interference can change interpretation. This does not approve these alternatives for every HbA1c platform or pediatric device.

Accepted specimen

Serum preferred; listed plasma option is lithium-heparin plasma

Named additive/container

Red-top, gel-barrier or lithium-heparin tube; Container excludes oxalate, EDTA and citrate plasma

A glucose order is not permission to choose any gray tube. This named test lists serum or lithium-heparin plasma; ongoing cell metabolism and the exact assay instructions matter.

It calls for separation from cells and explicit identification as serum or lithium-heparin plasma. Fluoride discussion does not remove its current matrix instructions.

The page also contains general fluoride discussion and an oxalate/NaF parenthesis in rejection wording. Do not infer gray-tube acceptance from those passages against the Container field; clarify the actual order with the lab. No generic fasting or time rule exported.

Accepted specimen

Citrate whole-blood tube submission or properly prepared citrate plasma, as specified

Named additive/container

Blue-top 3.2% buffered sodium citrate; a frozen-plasma path uses its named transport container

PT needs the intended citrate relationship. An acceptance limit is not a new collection target, and a tube of blood is not the same handling state as the frozen plasma prepared from it.

The method analyzes plasma. Its submission instructions distinguish target draw from acceptance minimum, winged-set dead space, high-hematocrit adjustment, and intact-tube versus prepared frozen-plasma workflow.

The cited PT method includes INR and named warfarin monitoring; it is not every anticoagulant-monitoring assay. Refrigerated specimens are rejected here. No adjustment recipe, inversion count or centrifuge program is exported.

Accepted specimen

Whole blood or plasma under its specified citrate workflow

Named additive/container

Blue-top 3.2% buffered sodium citrate

The same citrate cap does not make every aPTT specimen pathway identical. Therapy status is relevant information for this assay’s processing and transport requirements.

The method analyzes plasma. Storage instructions separately address heparin-treated patients, involving prompt testing or platelet-poor frozen plasma. That branch cannot be replaced by the ordinary paragraph.

No heparin dose timing, universal heparin monitoring rule, line-collection workaround, inversion count or centrifuge setting is exported. Follow the actual ordered method and treatment-related branch.

Accepted specimen

Citrate plasma; this submission example specifies frozen plasma

Named additive/container

Blue-top 3.2% buffered sodium citrate, with its specified frozen-plasma transport container

Two assays can begin with citrate blood and still require different submitted specimens. This D-dimer example asks for prepared plasma with a specific separation/transport pathway.

The collection paragraph calls for a two-stage separation process and transfer of prepared plasma; the frozen pathway must remain frozen. This differs from simply sending an intact PT tube.

No centrifuge settings, time allowances or universal device/discard rule is supplied here. The named page’s short-term nonfrozen exception does not approve all unprocessed citrate tubes. Clinical decision cutoffs are not exported.

Accepted specimen

Lithium-heparin plasma, frozen

Named additive/container

Green-top lithium heparin; the page also permits lithium-heparin plasma separator gel products

Troponin is a test family, not one universal tube choice. Labcorp 140150 is a specific high-sensitivity troponin T assay with a lithium-heparin plasma submission.

Transfer separated plasma to a plastic transport tube and identify it as lithium-heparin plasma. Other matrices are rejected by this named test.

This send-out specimen example does not define an acute-care testing timeline. Biotin and other interference matter; the page contains different biotin timing statements, so no stop/wait instruction is exported. Troponin elevation is not uniquely myocardial infarction.

Accepted specimen

Serum preferred or lithium-heparin plasma

Named additive/container

Red-top, gel-barrier or lithium-heparin tube; excludes oxalate, EDTA and citrate plasma

Ferritin assesses an iron-related question but does not share the CBC’s intact EDTA whole-blood requirements. This named ferritin method accepts specified serum/plasma matrices.

When using a red-top tube or plasma, separated liquid is transferred to a plastic transport tube. The original tube type and submitted liquid state are different decisions.

The fetched page shows duplicated/edited container and reference-range text. Its intact container statements agree on these matrices; no range table is exported. Ferritin also reflects inflammation, not iron stores alone.

Accepted specimen

Serum preferred or lithium-heparin plasma

Named additive/container

Red-top, gel-barrier or lithium-heparin tube; excludes oxalate, EDTA and citrate plasma

Knowing that TSH evaluates thyroid-related function does not establish its container. The selected method accepts particular serum/plasma matrices, not any available plasma tube.

Red-top or plasma submission calls for separated liquid in a plastic transport tube. Biotin information belongs to the assay-specific preparation/interference workflow.

Do not independently stop supplements/medicines or export a universal biotin interval. Disease, therapy and interference affect interpretation. Older clinical management paragraphs are not treated as current treatment guidelines.

Accepted specimen

Plasma

Named additive/container

Gray-top sodium fluoride/potassium oxalate or sodium fluoride/sodium heparin

The instruction for an unseparated collection tube and the instruction for separated plasma describe different stages. “Always ice lactate” and “room temperature throughout” both miss that distinction in this named example.

The collection-stage tube is chilled and plasma is promptly separated/transferred; the later Storage Instructions specify room temperature. Serum is rejected.

No timing, tourniquet, patient-preparation or centrifuge program is exported. This method does not establish requirements for bedside blood-gas lactate, every lactate assay or every gray additive.

A timed urine aliquot is not a complete clearance specimen by itself. The collection interval, total urine volume and corresponding blood measurement connect that small aliquot to the full measurement.

The request needs collection start and finish dates/times and total 24-hour volume; corresponding blood and urine are submitted together. Missing blood creatinine is a rejection cause.

Named specimen: Serum preferred or lithium-heparin plasma, plus a 24-hour urine aliquot

Named container scope: Listed blood serum/gel/lithium-heparin products; plastic urine container with or without the specified HCl preservative

Do not repeat the page’s broad assertion that any 24-hour test can share this specimen: other analytes can reject its preservative. No blood-timing window, fluid intake, medicine stopping or universal urine-storage rule exported.

The aliquot represents the defined timed collection. A random urine sample with the same container does not automatically replace that interval or its total-volume record.

Total 24-hour volume must accompany the specimen. Its collection interval integrates excretion rather than representing one spot cortisol measurement.

Named specimen: 24-hour urine aliquot for this LC/MS-MS assay

Named container scope: Plastic urine container; the page allows boric acid or HCl preservation

Preservative acceptance is assay-specific; no home preservative preparation is instructed. This example does not diagnose Cushing syndrome by itself or establish an adrenal-insufficiency test.

Container and preservative requirements depend on the ordered measurement. Even two timed urine chemistries may not accept the same preserved aliquot; the laboratory supplies the appropriate collection kit.

It separates urinalysis and culture preservative products; timed aliquots require total volume and an appropriately combined complete collection. Its preservative table names chloride urine as rejecting HCl, while calcium urine specifies HCl.

No generic timing, cooling, medication stopping, acidification recipe or complete patient procedure is exported. Follow the specific ordered test; do not substitute preservatives.